Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 15/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 14/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 12/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874420 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2819319 | 0.89 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2816007 | 0.87 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2818070 | 0.86 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL3566232 | 0.85 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2882248 | 0.84 | PIK3CB (0.80) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2880716 | 0.84 | PIK3CB (0.79) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2818127 | 0.83 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2814733 | 0.83 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL2816532 | 0.82 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | PIK3CB 4277/4885PIK3CA 2182/4885PIK3CD 3881/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | PIK3CB 4277/4885PIK3CA 2182/4885PIK3CD 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.